Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloretazine plus cytarabine versus placebo plus cytarabine in first-relapse acute myeloid leukemia
ACTRN12606000514505Phase 3Not yet recruiting
- Sponsor
- Vion Pharmaceuticals
- Start
- Nov 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Cloretazine + cytarabine with Placebo + cytarabine (2 arms). Primary endpoint: Overall response rate. Planned start Nov 2007; status: not yet recruiting.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12606000514505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000514505.